 |
SV Life Sciences Fund ISVLSF I closed in 1994 with total commitments of $100 million. As at 31 March 2010, SVLSF I had invested $123 million in 31 portfolio companies. To go to individual portfolio companies websites please click on company logo. SV Life Sciences Fund I (SVLSFI)
Allos Therapeutics: US - Exited
First investment: 1998 - Early Stage Allos Therapeutics was developing and commercializing innovative small molecule therapeutics for the treatment of cancer. 
Axys Pharmaceuticals: US - Exited
First investment: 1994 - Early Stage Axys developed a protease-inhibitor based products for cancer & inflammatory diseases. 
Cerebrus: UK - Exited
First investment: 1995 - Start Up Cerebrus CNS drug discovery (Acquired by Nigra, which was then bought by Vernalis) Coral Therapeutics: US - Exited First investment: 1994 - Start Up Coral was a provision of blood handling services to hospitals. 
Cytomed: US - Exited
First investment: 1997 - Early Stage Cytomed was a leukotriene inhibitors for asthma (Acquired by LeukoSite Inc and then by Millenium). Euro Dentalversand: Germany - Exited First investment: 2000 - Buyout Euro was mail order dental consumables. 
Geltex Pharmaceuticals: US - Exited
First investment: 1995 - Early Stage Further investment: 1998 - Expansion Geltex developed novel non-absorbed pharmaceuticals. Geltex was acquired by Genzyme Corporation after our exit. 
General Surgical Innovations: US - Exited
First investment: 1995 - Early Stage General Surgical Innovations is a minimally invasive approach to hernia repair and incontinence (purchased by United States Surgical). 
Genosis: UK - Exited
First investment: 1999 - Start Up Genosis has developed home use diagnostic devices to assess fertility in couples of childbearing age. Genosis’ products - Fertell, which provide both male and female tests, are available over the counter in the UK and the US and provide couples with the tools required to assess their fertility in the privacy of their homes. 
Heritage Health Systems: US - Exited
First investment: 1995 - Early Stage Heritage was a physician practice. 
Incyte Pharmaceuticals: UK - Exited
First investment: 1996 - Start Up Functional genomics (Acquired by Incyte). 
JC Nationwide: US - Exited
First investment: 1995 - Buyout JC Nationwide was a physician recruitment agency. 
Kinetix Pharmaceuticals: US - Exited
First investment: 1999 - Start Up Kinase targeted drug discovery (Acquired by Amgen). 
Leica Microsystems: Germany - Exited
First investment: 1998 - Buyout Leica Manufactured and marketed microscopes and neurosurgical equipment. 
LeukoSite: US - Exited
First investment: 1994 - Start Up LeukoSite was a treatment of Inflammatory diseases and cancer (Acquired by Millenium). 
MedNova: Ireland - Exited
First investment: 1996 - Start Up MedNova was a device for interventional radiology and cardiology. 
Metris Therapeutics: UK - Exited
First investment SVLSF I: 1998 - Start Up First investment SVLSF II: 2000 - Start Up Metris is a women’s healthcare company that is developing drugs for the treatment of chronic gynecological and menstrual conditions. 
Micromass: UK - Exited
First investment: 1996 - Buyout Micromass was a minimally invasive approach to hernia repair and incontinence (purchased by Waters). 
MicroMed: US - Exited
First investment: 1998 - Early Stage MicroMed based in Houston, TX, has developed an implantable pump for use as a Left Ventricular Assist Device (LVAD) to aid the heart’s pumping action in patients suffering from congestive heart failure. 
Micromet: Germany
First investment: 1998 - Start Up Micromet designs and develops novel antibody derived therapeutics for the treatment of cancer diseases. These drugs are unique in their ability to engage immune effector cells to selectively eliminate disease causing cells. Nexan: UK - Exited First investment: 1996 - Start Up Nexan was a remote telemonitoring devices. 
OMS Foundations: US - Exited
First investment: 1998 - Early Stage OMS Foundations was an oral maxillofacial physician practice management. 
Orthovita: US - Exited
First investment: 1997 - Early Stage Orthovita was a novel bone substitute materials company. Pelton & Crane: US - Exited First investment: 1997 - Buyout Pelton & Crane developed sterilization equipment. 
Shire Pharmaceuticals: US - Exited
First investment: 1994 - Early Stage Shire Pharmaceuticals - osteoporosis and Alzheimer's disease. 
Sirona Dental Systems: Germany - Exited
First investment: 1997 - Buyout Sirona was a dental equipment manufacturer. 
Strides Arcolab: India - Exited
First investment: 1997 - Expansion Strides Arcolab was a manufacturer of generic pharmaceuticals. 
TLC Vision: US - Exited
First investment: 1995 - Expansion TLC Vision was a service provider for laser-based ophthalmic surgery. Formerly known as Laservision. 
Triangle Pharmaceuticals: US - Exited
First investment: 1995 - Start Up Triangle Pharmaceuticals was an antiviral and anticancer drug development company (Acquired by Gilead). 
Vanguard Medica (Vernalis): UK - Exited
First investment: 1995 - Early Stage Vanguard Medica was an antiviral and anticancer drug development company. (Acquired by Vernalis) Vintage BioMed: US - Exited First investment: 1996 - Seed Vintage BioMed was a capital equipment leasing and maintenance company. 
| |
